Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
Business Wire•02/11/2026•16:02 ET
1
Key Highlights
- ➤Janux (JANX) will present initial JANX011 Phase 1 data on November 9, 2026.
- ➤Phase 1 study evaluates JANX011 safety, pharmacokinetics and pharmacodynamics in healthy volunteers.
- ➤JANX011 is Janux’s first clinical-stage ARM platform candidate targeting CD19.
- ➤Presentation will discuss JANX011’s autoimmune-disease development and broader ARM platform implications.
Expert Statements
David Campbell, President and Chief Executive Officer of Janux Therapeutics
“The presentation will review safety, pharmacokinetics and pharmacodynamic findings and discuss the implications of the study for the continued clinical development of JANX011 in autoimmune disease and for the broader ARM platform.”
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
Virtual event to be held on Monday, November 9, 2026, at 8:30 a.m. ET
Get started
Create a free account to read the full story.